Our team (ex Google, Meta, Palantir, Genentech, Eli Lilly, etc.) is working on accelerating drug discovery by building AI algorithms on top of a unique and growing proprietary data set and making those algorithms available to scientists via a carefully-designed “copilot” software platform for molecular design. We are backed by top investors (e.g. a16z, Lux), advised by renowned drug discovery experts, and have achieved product-market fit, with rapidly growing revenue and customer adoption.